Literature DB >> 6889511

The effect of derivatives of folic acid on the fluorodeoxyuridylate-thymidylate synthetase covalent complex in human colon xenografts.

J A Houghton, C Schmidt, P J Houghton.   

Abstract

This study was designed to examine the endogenous concentrations of 5,10-methylenetetrahydrofolate (CH2FH4) in human colorectal adenocarcinoma xenografts, and to determine the ability of other folate derivatives to increase the formation of the ternary covalent complex between CH2FH4, [6-3H]-5-fluorodeoxyuridylate (FdUMP) and thymidylate synthetase (TS, EC 2.1.1.45). Levels of CH2FH4 were determined by measuring the release of [3H]2O from [5-3H]-dUMP using TS from Lactobacillus casei. The reaction was linear from 1.9 X 10(-13) to 2.4 X 10(-11) mol of CH2FH4 assayed. Concentrations of CH2FH4 were low, ranging from 66 to 233 nM in cell water. Tetrahydrofolate (FH4) and dihydrofolate (FH2) increased complex formation, while 5-formyltetrahydrofolate (5-CHOFH4) and 5-methyltetrahydrofolate (5-CH3FH4) decreased the covalent binding of [6-3H]-FdUMP in vitro. Administration of FH4 or FH2 to tumor-bearing mice reduced subsequent formation of the covalent complex in vitro. Since 5-CH3FH4 is a major derivative of folate in mammalian tissues, its effect on the covalent binding of [6-3H]-FdUMP was examined further; even in the presence of homocysteine and cyanocobalamin (B12), the formation of the covalent complex was not increased. The fate of [5-14CH3]-FH4 was subsequently examined in vivo. In tumors at 1 hr after injection, 72% of the radiolabel remained as [5-14CH3]-FH4, while 17% had been converted to [14C]-methionine or incorporated into protein. By contrast, however, the incorporation of radiolabel into the protein fraction of liver was almost 30-fold greater at this time. At 4 hr, radioactivity in tumors (dpm/g) and in the fraction associated with [5-14CH3]-FH4 was decreased by over 60%, while metabolism was increased by only 13%. No polyglutamate forms of [5-14CH3]-FH4 were detected in tumors at 4 hr after treatment.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6889511     DOI: 10.1016/0277-5379(82)90005-0

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  16 in total

1.  Metabolic pathway for leucovorin.

Authors:  P G Rothberg
Journal:  Mol Diagn       Date:  2000-03

2.  A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions.

Authors:  H Bailey; G Wilding; K D Tutsch; R Z Arzoomanian; D Alberti; M B Tombes; J L Grem; D R Spriggs
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Proceedings of the British Pharmacological Society. 9th-11th September 1985. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1985-12       Impact factor: 8.739

4.  Folinic acid modulation of fluorouracil: tissue kinetics of bolus administration.

Authors:  C P Spears; B G Gustavsson; R Frösing
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850

5.  Phase I clinical trial of cisplatin given i.v. with 5-fluorouracil and high-dose folinic acid.

Authors:  J L Abbruzzese; R Amato; S Schmidt; M N Raber; P Frost
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  The modulation by L-leucovorin of 5-fluorouracil antitumor activity on human colon carcinoma cells in vitro and in vivo.

Authors:  S Kase; T Kubota; M Watanabe; T Takahara; T Takeuchi; H Yamaguchi; T Furukawa; T Teramoto; S Kodaira; K Ishibiki
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

7.  Phase II trial of 5-fluorouracil, high-dose leucovorin calcium, and dipyridamole in advanced prostate cancer.

Authors:  D Singh; J H Doroshow; L Leong; K Margolin; S Akman; J Raschko; G Somlo; R Morgan; J Harrison; J Cho
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

8.  The pharmacokinetics of reduced folates after intraperitoneal and intravenous administration of racemic [6S,R]-folinic acid.

Authors:  J H Sips; O van Tellingen; W J Nooijen; S Rodenhuis; W J Ten Bokkel Huinink; J H Beijnen
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

9.  Folinic acid effect on 5-fluorouracil kinetics in vivo.

Authors:  R Herrmann; J Reuter; R Port; H Osswald
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

10.  Schedule-dependency of in vivo modulation of 5-fluorouracil by leucovorin and uridine in murine colon carcinoma.

Authors:  J C Nadal; C J van Groeningen; H M Pinedo; G J Peters
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.